Elevated brain-derived cell-free DNA among patients with first psychotic episode - a proof-of-concept study

Early diagnosis in schizophrenia

Schizophrenia is a complex and chronic psychiatric disorder affecting around 1% of the global population. It is associated with increased disability, mortality and high private and social economic burden^1–3.

Psychosis is the first presentation of schizophrenia that usually leads to the diagnosis. Although psychosis typically onsets during adolescence and young adulthood, there is accumulating data that demonstrates underlying biological changes, beginning years prior to the psychotic symptoms^4,5. Thus, identifying biomarkers that will allow early diagnosis and therapeutic interventions is of the highest importance.

The etiology of schizophrenia is multifactorial, with a complex interaction of polygenic risk and environmental factors^3,6. Although over 100 genetic variants were identified contributing to the risk of schizophrenia, their broad distribution in the general population precludes clinical use⁷.

Other potential biomarkers were studied including neurotransmitters and their metabolites⁸, associated endophenotypes such as smooth pursuit eye movement (SPEM)⁹ and sensory gating defects (P150)¹⁰. Results of those studies are somewhat inconsistent and are not specific enough to allow their use as a diagnostic tool. Brain imaging has demonstrated notable structural changes mostly in late and more chronic stages of the disease, too late for useful intervention¹¹.

Cell free DNA as a biomarker for diseases

Circulating cell-free DNA (cfDNA) in the blood plasma was first discovered by Mandel and Metais in 1948¹². Over the years it was established that these typically ∼150 bp fragments of double-stranded DNA are released into the blood stream during the process of cell death¹³. cfDNA molecules are rapidly cleared from the circulation with a half-life of ∼15 minutes, thus reflecting events taking place at the time of blood draw^14,15. Although the mechanism underlying the release and rapid clearance of the cfDNA is still unclear, many researchers have been trying to develop methods that will enable the use of these short fragments for the diagnosis and follow-up of various medical conditions. For example, cfDNA-based methods of prenatal diagnosis have been developed^16,17, and ongoing work is advancing approaches for cancer liquid biopsy^18–20 and for detection of rejection in organ transplant recipients^15,21,22.

The possibility of using cfDNA as a biomarker in the medical conditions detailed so far is based on the fundamental genetic difference between the DNA of a host and that of a tumor, fetus or the graft^21,23–26. In comparison it is more complicated to assess changes in the levels of cfDNA in plasma of healthy individuals or individuals without mutated DNA in their blood. It is known that plasma levels of cfDNA vary over time depending on age, increased physical activity, and the existence of various medical conditions such as infectious diseases¹⁵. Therefore, it has not been possible to use the amount of cfDNA in the blood as a marker for a specific pathology. Moreover, although the cfDNA that circulates in the blood originates from different tissues, it has the same genome and therefore cannot be associated with a specific source tissue using DNA sequencing^23,27,28.

We and others have recently described an approach to identify the tissue origins of cfDNA, based on tissue-specific methylation patterns. Such cell-type specific markers allow the inference of cell death in multiple settings, for example cardiomyocyte cell death following myocardial infarction or hepatocyte death in patients with liver metastasis ^21,23–26.

Brain cell death in psychosis and schizophrenia

Neuro-anatomical changes are known in schizophrenia. Numerous longitudinal and cross-sectional imaging studies recruited individuals at high and ultra-high risk for developing a psychotic illness and demonstrated dynamic brain changes emerging around onset and over the years of schizophrenia. The studies generally demonstrate gray matter reduction in the frontal and temporo-limbic regions^29–31. Structural brain abnormalities in psychosis occur prior to full blown symptoms and progressively worsen as psychosis develops. Although the underlying causes and the exact timing of the morphologic changes in the brain remain obscure, apoptosis has been proposed as a potential mechanism that could contribute to this progressive pathology. This idea is also supported by post-mortem evidence of regional reduction of neuronal and glia density. Apoptosis in the CNS occurs rapidly, and apoptotic cells are typically cleared within 24 hours. The process occurs without inflammation and does not involve gliosis^32,33. Ershove et. al demonstrated dysregulation of apoptosis in schizophrenia through considerably increased oxidated levels of cfDNA³⁴. Thus, we hypothesized that brain-derived cfDNA levels increase in patients with acute psychosis and schizophrenia, reflecting ongoing cell death, especially in early and active phases of diseases. We further hypothesized that brain cfDNA levels would be increased in patients, unrelated to treatment with antipsychotic medications.

In this proof-of-concept study we examined plasma samples from patients with a first psychotic episode, in order to assess the potential use of brain cfDNA as a method for early detection and diagnosis of schizophrenia in general and acute psychosis events.

Clinical samples

We recruited men and women over 18 years of age, who have developed psychotic symptoms for the first time in their life within the last year and were admitted to the acute psychiatric units of the Jerusalem Mental Health Center in Israel. Diagnosis of a psychotic disorder was given by treating psychiatrists and verified by a senior psychiatrist from the research team (I.P.). Blood samples were obtained after the initial stabilization and partial remission of the psychotic symptoms which enabled the patients to give written informed consent for participation in the study. The patients were asked to complete a short questionnaire regarding demographic details, current physical condition, the onset of present symptoms and drug use. The recruitment was done following the approval of the study’s protocol by the Jerusalem Mental Health Center Institutional Review Board. Patients with acute medical conditions in the week prior to the blood sampling were excluded from the study.

A total of 31 patients were recruited between the years 2017 and 2019. DNA extraction from two samples has failed, and the remaining 29 samples were analyzed. The study included 55% females (n=16) and 45% males (n=13), with an age distribution of 18-48 years (average 24). 72.5% of the patients (n=21) were hospitalized with a first psychotic event in their life, and 27.5% of the patients (n=8) had a second or third psychotic event, up to a year after the beginning of the first one. 44.8% of the patients (n=13) did not have any background of drug abuse, 31% (n=9) indicated the use of marijuana in the weeks preceding the onset of the first psychotic episode. 24.2% patients (n=7) described using several different types of drugs (hallucinogens, MDMA, cocaine, etc.) in the past. Clinical data, including medications used, were obtained from medical records. 31 adult volunteers participated in the study as unpaid healthy controls. The samples were compared to age and sex matched healthy control subjects.

Patient demographics, clinical data and cfDNA data are detailed in Supplementary Table S1.

cfDNA analysis

Blood samples were collected in cell-free DNA BCT® (Streck) tubes and centrifuged at 1500g for 10 min at 25 °C within 1 week of collection. Plasma was removed and re-centrifuged at 3000g for 10 min at 25 °C to remove any remaining cells. Plasma was then stored at −80 °C until assay. Cell-free DNA was extracted using the QIAsymphony SP instrument and its dedicated QIAsymphony Circulating DNA Kit (Qiagen) according to manufacturer’s instructions. DNA concentration was measured using the Qubit® dsDNA HS Assay Kit (Thermo Fisher Scientific). cfDNA was treated with bisulfite using EZ DNA Methylation-Gold™ (Zymo Research), and PCR amplified with primers specific for bisulfite-treated DNA but independent of methylation status at the monitored CpG sites, as described³⁵. Treatment with bisulfite led to degradation of 60–90% of the DNA (average, 75% degradation), consistent with previous reports³⁶. Note that while DNA degradation does reduce assay sensitivity (since fewer DNA molecules are available for PCR amplification), it does not significantly harm assay specificity since methylated and unmethylated molecules are equally affected. Primers were bar-coded using TruSeq Index Adapters (Illumina), allowing the mixing of samples from different individuals when sequencing PCR products using NextSeq sequencers (Illumina). Sequenced reads were separated by barcode, aligned to the target sequence, and analyzed using custom scripts written and implemented in R. Reads were quality filtered based on Illumina quality scores, and identified by having at least 80% similarity to target sequences and containing all the expected CpGs in the sequence. CpGs were considered methylated if CG was read and were considered unmethylated if TG was read.

The fraction of unmethylated molecules in a sample was multiplied by the total concentration of cfDNA in the sample, to assess the number of brain genome equivalents per ml of plasma. The concentration of cfDNA was measured prior to bisulfite conversion, rendering the assay robust to potential inter-sample fluctuations in the extent of bisulfite-induced DNA degradation.

Identification of brain methylation markers

Tissue-specific methylation markers were selected after a comparison of extensive genome-wide DNA methylation datasets generated using Illumina Infinium HumanMethylation450k BeadChip array. Datasets used included publicly available methylation profiles from The Cancer Genome Atlas and Gene Expression Omnibus repositories, along with data that we generated locally. Using this comparative analysis we selected 13 genomic loci, which are unmethylated specifically in neurons (4 markers), oligodendrocytes (3 markers), or astrocytes (3 markers) and in all brain-derived cell types (3 markers), and methylated in all other examined cell types. Data describing the development and validation of these 10 cell-specific markers (neurons, oligodendrocytes and astrocytes) were published in a recent paper³⁷. To test our in silico predictions regarding the 3 whole brain markers specificity, we applied bisulfite treatment, multiplex PCR and next-generation sequencing to determine the methylation status of each marker in a panel of DNA samples obtained from multiple human tissues, as previously described³⁵ (Figure 1-figure supplement 1A). To determine assay sensitivity, we serially diluted brain DNA into leukocyte DNA, and found that the brain markers allowed the detection of as little as 0.1% brain DNA in a mixture, or just one brain genome in a mixture of a thousand genomes (Figure 1-figure supplement 1B).

Noninvasive detection of brain-derived cfDNA among patients with first psychotic episode

We determined the plasma concentrations of brain-derived cfDNA (including methylation markers of neurons, astrocytes, and oligodendrocytes and whole brain) in 31 healthy controls, and 29 patients with first psychotic episode.

Total levels of cfDNA circulating in plasma were higher in patients with first psychotic episode compared with healthy controls (Mann–Whitney test for controls vs. patients, p-value =0.017, Figure 1A). cfDNA levels from all brain cell combined were higher in patients with first psychotic episode compared with healthy (Figure 1B,C). cfDNA levels from each brain cell type separately or from whole-brain markers were also significantly elevated in patients (Mann– Whitney test for patients vs controls, neurons p-value =0.0013, astrocytes p-value =0.0016, oligodendrocytes p-value =0.0129, whole brain markers p-value = 0.0012). Elevated brain-derived cfDNA was seen when measuring either its absolute concentration (Figure 1D), or its fraction (Figure 1-figure supplement 2A-D). This is consistent with elevated release of brain-derived cfDNA in patients with first psychotic episode, reflecting brain pathology, rather than a non-specific effect.

• Download figure
• Open in new tab

Figure 1: Brain-derived cfDNA in patients with a first psychotic episode.

A. Plasma concentrations of total cfDNA. Total levels of cfDNA in healthy controls and patients with first psychotic episode. Mann–Whitney test for controls vs. patients, p-value =0.017.

B-C. Plasma concentrations of brain-derived cfDNA. Brain cfDNA levels in healthy controls (n=31) and patients with first psychotic episode (n=29), represented as the cumulative sum of the average signals from neuron, oligodendrocyte and astrocyte markers. In panel B, graph retaining the value of each component; in panel C, graph combining all average signals to one value for statistical analysis.

D. Signals from distinct brain cell types. Mann–Whitney test for controls vs. patients, neurons p-value =0.0013, astrocytes p-value =0.0016, oligodendrocytes p-value =0.0129 and whole brain markers p-value =0.0012. Shown are the average levels in plasma of 4 neuronal markers, 3 astrocyte markers, 3 oligodendrocyte markers, and 3 general brain markers. cfDNA was treated with bisulfite, PCR amplified and sequenced, and the molecules that are fully unmethylated were scored. The fraction of brain-specific molecules was multiplied by the total cfDNA concentration. Each dot represents one plasma sample.

E. ROC curve for distinguishing patients with first psychotic episode from healthy controls.

A combined score of all brain markers, area under the curve (AUC) 0.77; 95% CI =0.64-0.9; p-value = 0.0003.

To determine how well brain-derived cfDNA markers can distinguish patients with first psychotic episode from healthy controls, we generated a receiver operating characteristic (ROC) curve for the combined signal from all brain cell types. The brain cfDNA score was able to identify the plasma of patients with a first psychotic episode with an area under the curve (AUC) of 0.77 (p value=0.0003). At 90% specificity, the sensitivity for identifying patients with first psychotic episode was 65% (Figure 1E). The markers of each brain cell type were able to identify the plasma of patients with first psychotic episode with an AUC of 0.65-0.73 (Figure 1-figure supplement 2E-H).

There was no significant correlation between brain markers and clinical parameters including the duration of the current episode, duration of hospitalization or the number of psychotic episodes (see Data Table S1).

Relationship to psychiatric drugs

Since previous studies found a correlation between the use of antipsychotic drugs and anatomic changes in the brain³⁸, we examined whether the increase of brain-derived cfDNA levels in patients is related to their psychiatric drug intake. To this effect, we considered (1) the amount of antipsychotic drugs taken on the day of the patient’s blood test for cfDNA, and (2) the total amount of antipsychotic drugs taken throughout the hospitalization until the blood test. These data were taken from medical records. In order to generate a single score for all patients, independently of the type of drugs they took, we converted the various antipsychotic medication dosages into an equivalent dosage of olanzapine, following the expert-consensus based method used in Gardner et. al (2010)³⁹. We then ran various statistical tests (Pearson and Spearman correlation coefficients, and t-test and Mann-Whitney for categorical comparisons), to examine potential correlations with the total amount of cfDNA, and the level of cfDNA originating from astrocytes, neurons, oligodendrocytes, and from the whole brain. We considered 13 individual biomarkers for brain cell types, as well as their average for each cell type, for a total of 18 variables.

After correcting for multiple testing, we did not find any statistically significant correlation between drug intake and cfDNA. Also, all statistical tests apart from 3 were non-significant on a nominal level (p>0.05). We found nominally statistically significant correlations between the levels of brain-derived cfDNA and drug intake for only one type of astrocyte marker (PRDM2) and one type of neuron marker (ITF) (Spearman correlation coefficient for astrocyte marker PRDM2: p-value=0.024/drugs on blood test day, and p-value=0.025/overall amount drugs; for neuron ITF: p-value=0.016/overall amount of drugs).